8-K: BioCardia Reports Positive Chronic Myocardial Ischemia Trial Results

BioCardia's CardiAMP CMI trial preliminary results show durable improvements in exercise tolerance and reduced angina in patients with chronic myocardial ischemia.

Summary

• BioCardia announced the oral presentation of preliminary results from the CardiAMP Cell Therapy in Chronic Myocardial Ischemia Trial (CardiAMP CMI) open-label cohort at the EuroPCR conference.
• The minimally invasive CardiAMP Cell Therapy procedure was well-tolerated, with no treatment-emergent major adverse cardiac events.
• Patients demonstrated positive clinical outcomes, including increased exercise tolerance and reduced angina episodes, persisting up to two years post-treatment.
• Exercise tolerance improved by an average of 179 seconds, and angina episodes were reduced by an average of 82% by six months.
• These results support the CardiAMP cell therapy approach for patients suffering from refractory angina, a condition impacting 600,000 to 1.8 million patients in the U.S.
• The CardiAMP Cell Therapy is designated by the FDA as a Breakthrough Therapy for Ischemic Heart Failure and uses a patient's own bone marrow cells.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive development, with preliminary trial results showing significant clinical benefits and FDA Breakthrough Therapy designation providing strong validation for the cell therapy approach.

Positives

• The CardiAMP Cell Therapy procedure was well-tolerated with no treatment emergent major adverse cardiac events.
• Patients experienced increased exercise tolerance, improving by an average of 179 seconds, which persisted for the two-year study follow-up.
• Angina episodes were reduced by an average of 82% by six-months after treatment.
• The therapy has shown a positive impact on both exercise tolerance and angina episodes in patients with refractory angina.
• The CardiAMP Cell Therapy is designated by the FDA as a Breakthrough Therapy for Ischemic Heart Failure.
• Medicare reimbursement is available for both treatment and control procedures for the CardiAMP cell therapy trials.

Negatives

• The presented results are from a preliminary open-label cohort, not a randomized controlled trial.
• The therapy is still investigational and limited by United States law to investigational use.

Risks

• The company's liquidity position and ability to raise additional funds could impact its ability to advance clinical trials.
• Actual results may differ materially from forward-looking statements due to various risks and uncertainties.
• Factors that could materially affect actual results are detailed in BioCardia's Form 10-K filed on March 24, 2026.

Future Outlook

The results support the continued clinical development of the CardiAMP cell therapy approach for patients suffering from refractory angina. The company is advancing its clinical stage product candidates and has proprietary delivery and navigation platforms.

Management Comments

• "A cell-based approach, added to this medical therapy, has potential to better manage these symptoms and improve the quality of life."
• "We are thankful for the physician scientists who contributed their great experience to this program as well as the patients who participated."
• "These results support this CardiAMP cell therapy approach which has potential to help patients suffering from refractory angina."
• "To our knowledge, only cell therapy has had a positive impact on both exercise tolerance and angina episodes in these patients."

Industry Context

StockSavvy.ai notes that BioCardia's announcement highlights a significant unmet need in cardiovascular disease treatment, particularly for patients with refractory angina who have exhausted conventional options. The positive preliminary results for their cell therapy approach, if validated in larger trials, could position BioCardia as a key player in regenerative medicine for heart conditions.

Stakeholder Impact

• Shareholders may see increased confidence in the company's lead therapeutic candidate.
• Patients with chronic myocardial ischemia and refractory angina may benefit from a new, potentially effective treatment option.
• Healthcare providers may gain a new therapeutic tool for managing severe cardiovascular conditions.

Next Steps

• Continued clinical development of the CardiAMP cell therapy.
• Further evaluation of the therapy's potential to help patients suffering from refractory angina.

Key Dates

Recommendation

While the preliminary results are encouraging and the FDA designation is positive, the therapy remains investigational. Further data from larger, controlled trials are needed to confirm efficacy and safety before a stronger recommendation can be made. The company's liquidity also remains a factor.

Keywords

BioCardia, CardiAMP, Chronic Myocardial Ischemia, Cell Therapy, Refractory Angina, Cardiovascular Disease, Clinical Trial Results, EuroPCR